M Vatca1, J T Lucas2, J Laudadio3, R B D'Agostino4, J D Waltonen5, C A Sullivan6, R Rouchard-Plasser7, M Matsangou8, J D Browne9, K M Greven10, M Porosnicu11. 1. Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: mvatca@wakehealth.edu. 2. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: jolucas@wakehealth.edu. 3. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: jlaudadio@uams.edu. 4. Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: rdagosti@wakehealth.edu. 5. Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA; Department of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: jwaltone@wakehealth.edu. 6. Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA; Department of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: csulliva@wakehealth.edu. 7. Department of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: rplasser@wakehealth.edu. 8. Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: mmatsang@wakehealth.edu. 9. Department of Otolaryngology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: jdbrowne@wakehealth.edu. 10. Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: kgreven@wakehealth.edu. 11. Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC 27157, USA. Electronic address: mporosni@wakehealth.edu.
Abstract
OBJECTIVES: The standard concurrent radiotherapy and chemotherapy regimens for patients with oropharyngeal cancer are highly toxic. Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has recently emerged as a distinct biological and clinical entity with improved response to treatment and prognosis. A tailored therapeutic approach is needed to optimize patient care. The aim of our study was to investigate the impact of HPV and smoking status on early toxicities (primarily mucositis) associated with concurrent chemotherapy and radiotherapy in patients with OPSCC. MATERIALS AND METHODS: We retrospectively evaluated 72 consecutive patients with OPSCC and known HPV status treated with concurrent radiotherapy and chemotherapy at our institution. Treatment-related toxicities were stratified by smoking and HPV status and compared using univariate and multivariate logistic regression. RESULTS: HPV-positive patients had a 6.86-fold increase in the risk of having severe, grade 3-4 mucositis. This effect was preserved after adjusting for patient smoking status, nodal stage, radiotherapy technique and radiotherapy maximum dose. Additionally, HPV status had significant effect on the objective weight loss during treatment and at three months after treatment. Consistently, non-smokers had a significant 2.70-fold increase in the risk of developing severe mucositis. CONCLUSION: Risk factors for OPSCC modify the incidence of treatment-related early toxicities, with HPV-positive and non-smoking status correlating with increased risk of high grade mucositis and associated outcomes. Retrospective single-institution studies need to be interpreted cautiously. However, this finding is important to consider when designing therapeutic strategies for HPV-positive patients and merits further investigation in prospective clinical trials.
OBJECTIVES: The standard concurrent radiotherapy and chemotherapy regimens for patients with oropharyngeal cancer are highly toxic. Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has recently emerged as a distinct biological and clinical entity with improved response to treatment and prognosis. A tailored therapeutic approach is needed to optimize patient care. The aim of our study was to investigate the impact of HPV and smoking status on early toxicities (primarily mucositis) associated with concurrent chemotherapy and radiotherapy in patients with OPSCC. MATERIALS AND METHODS: We retrospectively evaluated 72 consecutive patients with OPSCC and known HPV status treated with concurrent radiotherapy and chemotherapy at our institution. Treatment-related toxicities were stratified by smoking and HPV status and compared using univariate and multivariate logistic regression. RESULTS:HPV-positive patients had a 6.86-fold increase in the risk of having severe, grade 3-4 mucositis. This effect was preserved after adjusting for patient smoking status, nodal stage, radiotherapy technique and radiotherapy maximum dose. Additionally, HPV status had significant effect on the objective weight loss during treatment and at three months after treatment. Consistently, non-smokers had a significant 2.70-fold increase in the risk of developing severe mucositis. CONCLUSION: Risk factors for OPSCC modify the incidence of treatment-related early toxicities, with HPV-positive and non-smoking status correlating with increased risk of high grade mucositis and associated outcomes. Retrospective single-institution studies need to be interpreted cautiously. However, this finding is important to consider when designing therapeutic strategies for HPV-positive patients and merits further investigation in prospective clinical trials.
Authors: K K Ang; A Trotti; B W Brown; A S Garden; R L Foote; W H Morrison; F B Geara; D W Klotch; H Goepfert; L J Peters Journal: Int J Radiat Oncol Biol Phys Date: 2001-11-01 Impact factor: 7.038
Authors: Felix Y Feng; Hyungjin M Kim; Teresa H Lyden; Marc J Haxer; Francis P Worden; Mary Feng; Jeffrey S Moyer; Mark E Prince; Thomas E Carey; Gregory T Wolf; Carol R Bradford; Douglas B Chepeha; Avraham Eisbruch Journal: J Clin Oncol Date: 2010-04-26 Impact factor: 44.544
Authors: Daniel W Vermeer; William C Spanos; Paola D Vermeer; Annie M Bruns; Kimberly M Lee; John H Lee Journal: Int J Cancer Date: 2013-02-12 Impact factor: 7.396
Authors: Boudewijn J M Braakhuis; Maarten P Tabor; C René Leemans; Isaac van der Waal; Gordon B Snow; Ruud H Brakenhoff Journal: Head Neck Date: 2002-02 Impact factor: 3.147
Authors: Mary Roz Timbang; Michael W Sim; Arnaud F Bewley; D Gregory Farwell; Avinash Mantravadi; Michael G Moore Journal: Hum Vaccin Immunother Date: 2019-05-07 Impact factor: 3.452
Authors: Anna C H Willemsen; Ann Hoeben; Roy I Lalisang; Ardy Van Helvoort; Frederik W R Wesseling; Frank Hoebers; Laura W J Baijens; Annemie M W J Schols Journal: J Cachexia Sarcopenia Muscle Date: 2019-09-19 Impact factor: 12.910
Authors: Rebecca T Karsten; Najiba Chargi; Lisette van der Molen; Rob J J H van Son; Remco de Bree; Abrahim Al-Mamgani; Jan P de Boer; Frans J M Hilgers; Michiel W M van den Brekel; Ludi E Smeele; Martijn M Stuiver Journal: Eur Arch Otorhinolaryngol Date: 2021-05-27 Impact factor: 2.503
Authors: Frans J Mulder; Damiana D C G Pierssens; Laura W J Baijens; Bernd Kremer; Ernst-Jan M Speel Journal: Head Neck Date: 2020-10-23 Impact factor: 3.147